Colorectal liver metastases, Recurrence, Radiofrequency ablation, Radioembolization
Conditions
Interventions
The standard treatment is Radiofrequency Ablation (RFA) for colorectal liver metastases (CRLM). Patients will not be randomized. All patients will additionally be treated with Yttirum-90 Radioemboliza
Sponsors
Prof. Dr. R. van Hillegersberg
University Medical Center Utrecht
Department of Surgery
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients who have signed written informed consent; 2.Patients undergoing open, laparoscopic or percutaneous RFA treatment; 3.Aged 18 years or older; 4.ECOG performance status of 0-2; 5.Subjects with at least one and a maximum of five measurable lesion according to the RECIST criteria (5.0 cm or smaller in axial plane) on pre-operative imaging; 6.Normal renal and liver function tests at baseline (as described above).
Exclusion criteria
Exclusion criteria: 1.Irresectable extrahepatic metastases; 2.Liver resection; 3.Pregnant or breast-feeding patients; 4.Any form of chemotherapy within 2 months prior to the Y-90 radioembolization; 5.Exclusion criteria of radioembolization: - Compromised main portal vein; - Uncorrectable extrahepatic shunting to the gastrointestinal tract; - Unacceptable shunting to the lungs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local Liver Recurrence Rate (defined as radiologic detection of residual or recurrent viable tumor which is related to the ablation zone, located in the same segment as the treated lesion) | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment related adverse events Intrahepatic recurrences | — |
Contacts
Public ContactM. Samim
University Medical Center Utrecht Department of Surgery Heidelberglaan 100
Outcome results
None listed